Investment Type: Venture Capital
Investment Stage: Series A
Portfolio 4
| Date | Name | Website | Total Raised | Location |
| 03.04.2026 | Syneron Bi... | syneronbio.com | $150M | China |
| 08.09.2025 | Rapafusyn | rapafusyn.com | $72M | United Sta... |
| 10.08.2025 | Minghui Ph... | minghuipharma.com | $131M | China |
| 15.12.2021 | Cargene Th... | cargene.com | $19.2M | Singapore |
Mentions in press and media 12
| Date | Title | Description |
| 07.05.2026 | Global drugmakers eye more China biotech deals after record year | Global pharmaceutical executives are hungry for more deals with Chinese biotechnology companies after a record year, even as a stock market boom shows signs of cooling down. 2025 was a breakout year for China’s biopharma industry. Out-licen... |
| 04.04.2026 | Syneron Bio Fuels Innovation with $150M Investment | Syneron Bio secured $150 million in Series B financing. This major investment drives its intelligent Synova platform. The capital fuels advanced macrocyclic peptide drug discovery. It targets critical unmet needs across oncology, autoimmune... |
| 03.04.2026 | Syneron Bio Closes $150M Series B Financing | Syneron Bio, a Beijing, China-based intelligent platform-driven macrocyclic peptide drug discovery company, closed a $150m Series B financing round. The round was led by an international life-science fund, with co-lead participation from De... |
| 03.04.2026 | Syneron Bio: $150 Million Raised For Macrocyclic Peptide Drug Discovery Platform And Pipeline Advancement | Syneron Bio announced the completion of a $150 million Series B financing round, strengthening its position as a developer of intelligent platform-driven macrocyclic peptide therapeutics and accelerating its push toward clinical development... |
| 03.04.2026 | Syneron Bio Announces Completion of $150 Million Series B Financing | BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international ... |
| 16.12.2025 | BlossomHill Therapeutics Raises $84M in Series B Extension Funding | BlossomHill Therapeutics, Inc., a San Diego, CA-based clinical-stage biopharmaceutical company, raised $84M in Series B extension funding. The round was led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, and participati... |
| 08.09.2025 | Rapafusyn Pharmaceuticals Closes $44M Series A Financing | Rapafusyn Pharmaceuticals, a Baltimore, MD-based company which specializes in the discovery and development of non-degrading molecular glue therapeutics, raised $44M in Series A funding. The round was led by BioTrack Capital and Yonjin Capi... |
| 11.08.2025 | Minghui Pharmaceutical Raises USD 131M in Pre-IPO Financing | Minghui Pharmaceutical, a Singapore-based clinical biopharmaceutical company, raised USD 131M Pre-IPO financing. The round was led by new investors OrbiMed and co-led by Qiming Venture Partners with participation from existing investor TF C... |
| 10.08.2025 | OrbiMed, Qiming lead $131m pre-IPO financing for late-stage clinical biopharma Minghui | Global healthcare investment firm OrbiMed and Qiming Venture Partners have jointly led a pre-IPO financing of $131 million in Minghui Pharmaceutical, a Chinese late-stage clinical biopharmaceutical company, according to a statement. Shangha... |
| 07.08.2025 | Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion | SHANGHAI, Aug. 7, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led... |
Show more